Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abuse-Deterrent Testimony: Hamburg Defends Opioid Policy On The Hill

This article was originally published in The Pink Sheet Daily

Executive Summary

“It doesn’t do any good to label something as abuse-deterrent if it actually isn’t,” the FDA Commissioner tells senators. “And right now, unfortunately, the technology is poor.”

You may also be interested in...

Campaign Against Woodcock’s US FDA Commissioner Bid Has Begun

Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?

Alzheimer’s Can Follow HIV And Become Chronic Condition If Science Advances, Woodcock Argues

The acting US FDA commissioner equates drug development in the neurodegenerative diseases to work on HIV.

BsUFA III Negotiations Nearly Done; Commitment Letter Being Written

Supplement approval timeline and regulatory science issues apparently have been resolved.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts